[Evaluation of new agents with expected antiatheromatous action].
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy*; D002599:Chalcone / Q000008:administration & dosage* / Q000031:analogs & derivatives; D047188:Chalcones; D004353:Drug Evaluation, Preclinical; D004400:Dyphylline / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004952:Esters; D008297:Male; D011427:Propiophenones / Q000008:administration & dosage*; D051381:Rats; D013806:Theophylline / Q000031:analogs & derivatives*
D047188:Chalcones; D004952:Esters; D011427:Propiophenones; D004400:Dyphylline; C031742:2'-hydroxy-4-methoxychalcone; D002599:Chalcone; C031743:dyphylline clofibrinate; C031744:dyphylline nicotinate; D013806:Theophylline
Wartościowanie nowych zwiazków o spodziewanym działaniu przeciwmiazdzycowym.